Sex, amyloid, and <i>APOE</i> ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well‐characterized cohorts
Rachel F. Buckley(Harvard University), Vincent Doré(Australian e-Health Research Centre), Reisa A. Sperling(Harvard University), Aaron P. Schultz(Harvard University), Dylan Kirn(Brigham and Women's Hospital), Christopher C. Rowe(The University of Melbourne), Michael Donohue(Alzheimer’s Disease Neuroimaging Initiative), Jennifer S. Rabin(Sunnybrook Health Science Centre), Yen Ying Lim(The University of Melbourne), Bernard Hanseeuw(Cliniques Universitaires Saint-Luc), Colin L. Masters(Mental Health Research Institute), Victor L. Villemagne(The University of Melbourne), Paul Maruff(The University of Melbourne), Trey Hedden(Harvard University), Kathryn V. Papp(Brigham and Women's Hospital), Elizabeth C. Mormino(Allen Institute for Brain Science), Samantha C. Burnham(Edith Cowan University), Michael Waller(The University of Queensland), Annette J. Dobson(The University of Queensland), Rebecca E. Amariglio(Harvard University), Michael J Properzi(Massachusetts General Hospital), Jasmeer P. Chhatwal(Harvard University), Keith A. Johnson(Brigham and Women's Hospital), Heidi I.L. Jacobs(Harvard University), Dorene M. Rentz(Brigham and Women's Hospital)
Cited by 289
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k